Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 342-344

  Rosenson, Robert S ^a   Abby, Stacey L ^b   Jones, Michael R ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Apolipoprotein B; Colesevelam HCl; LDL particles; LDL cholesterol; Lipoprotein subclasses; Small LDL particles; Total cholesterol; Type 2 diabetes

Indexed keywords

COLESEVELAM; HEMOGLOBIN A1C; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLACEBO; VERY LOW DENSITY LIPOPROTEIN;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METFORMIN; MIDDLE AGED; PARTICLE SIZE; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349121043     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.09.026     Document Type: Letter

References (5)

1. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
2. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the ADA and the ACC Foundation. Diabetes Care 31 (2008) 811-822
3. Zieve F.J., Kalin M.F., Schwartz S.L., Jones M.R., and Bailey W.L. Results of the Glucose-Lowering Effect of Welchol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29 (2007) 74-83
4. Goldfine A.B. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 23 (2008) 502-511
5. Bays H., and Goldberg R. The "forgotten" bile acid sequestrants: is now a good time to remember?. Am J Ther 14 (2007) 567-580